Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs

SUMMARY Leveraging historical data into the design and analysis of phase 2 randomized controlled trials can improve efficiency of drug development programs. Such approaches can reduce sample size without loss of power. Potential issues arise when the current control arm is inconsistent with historic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmaceutical statistics : the journal of the pharmaceutical industry 2020-05, Vol.19 (3), p.276-290
Hauptverfasser:	Smith, Claire L., Thomas, Zachary, Enas, Nathan, Thorn, Katharine, Lahn, Michael, Benhadji, Karim, Cleverly, Ann
Format:	Artikel
Sprache:	eng
Schlagworte:	Bayes Theorem Bayesian Bayesian analysis borrowing Brain Neoplasms - drug therapy Brain Neoplasms - mortality Clinical trials Clinical Trials, Phase II as Topic - statistics & numerical data covariates Data Interpretation, Statistical Drug development Glioblastoma - drug therapy Glioblastoma - mortality historical data Historically Controlled Study - statistics & numerical data Humans Models, Statistical Oncology Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - mortality Pharmacology Randomized Controlled Trials as Topic - statistics & numerical data Research Design - statistics & numerical data Sample Size Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!